All In Biotech

Drug Trial Radar · NCT00729651

Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)

A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women

Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 343 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

343

Actual

Start

Mar 20, 2008

Primary completion

Apr 10, 2009

Study completion Apr 10, 2009

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the efficacy/safety of Fosamax Plus D

Conditions

  • Osteoporosis Postmenopausal

Interventions

  • alendronate sodium (+) cholecalciferolDrug

    Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks

  • Comparator: Alendronate sodium (Fosamax)Drug

    Alendronate sodium; tablet, once weekly, for 16 weeks

  • Comparator: CalciumDietary supplement

    500 mg oral tablet calcium once daily, for 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of TreatmentTime frame: 16 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.